News Search Results
Apr 04, 2025, 09:10 ET NeuroSense Therapeutics to Present New Data from PrimeC's Phase 2b Trial in ALS at the Annual American Academy of Neurology Meeting
April 4, 2025 /PRNewswire/ -- NeuroSense Therapeutics, Ltd. (NASDAQ: NRSN), a leading clinical-stage biotechnology company focused on developing treatments for severe neurodegenerative diseases, today announced that two members of its Scientific Advisory Board
More news about: NeuroSense
Apr 04, 2025, 09:00 ET Reishi™ Enters a New Era of Interior Design with Its First Industrial Collaboration with Ligne Roset
MycoWorksIn 2013, artists Philip Ross and Sophia Wang founded MycoWorks, a biotechnology dedicated to growing the future of materials. MycoWorks' patented Fine Mycelium™ platform engineers mycelium as it grows, crafting biomaterials
More news about: MycoWorks
Apr 04, 2025, 08:05 ET Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
employees vesting over four years with a one-year cliff. About RigelRigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders
More news about: Rigel Pharmaceuticals, Inc.
Apr 04, 2025, 08:00 ET Neurocrine Biosciences Appoints Dr. Sanjay Keswani as Chief Medical Officer
pharmaceutical companies and small biotechnology firms – and was instrumental in the development of several first-in-class and best-in-class approved medicines. Before joining Neurocrine, he was the President and Chief Executive Officer of ImmunoBrain, a clinical-stage biotechnology firm focused on developing
More news about: Neurocrine Biosciences, Inc.
Apr 04, 2025, 05:45 ET Contact Levi & Korsinsky by May 20, 2025 Deadline to Join Class Action Against Sana Biotechnology, Inc.(SANA)
April 4, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Sana Biotechnology, Inc. ("Sana Biotechnology, Inc." or the "Company") (NASDAQ: SANA) of a class action securities lawsuit.
More news about: Levi & Korsinsky, LLP
Apr 04, 2025, 05:45 ET ICON Public Limited Company Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before April 11, 2025 to Discuss Your Rights - ICLR
insufficient to shield the Company from the adverse effects of a significant market downturn; (c) the requests for proposals ICON received from its biotechnology customers during the Class Period were used in substantial part as price discovery tools, and thus were not indicative of underlying client demand;
More news about: Levi & Korsinsky, LLP
Apr 04, 2025, 03:42 ET AIM Congress 2025 Kicks Off in Abu Dhabi on Monday with 20,000 Participants
cover diverse sectors, including intelligent agriculture, energy, infrastructure, finance and capital markets, ICT, manufacturing, medical tourism, biotechnology, medical technology, pharmaceuticals, international trade, logistics and transportation, water technology, tourism and education. Roundtable
More news about: AIM Congress
Apr 04, 2025, 03:34 ET AIM Congress 2025 Kicks Off in Abu Dhabi on Monday with 20,000 Participants
cover diverse sectors, including intelligent agriculture, energy, infrastructure, finance and capital markets, ICT, manufacturing, medical tourism, biotechnology, medical technology, pharmaceuticals, international trade, logistics and transportation, water technology, tourism and education. Roundtable
More news about: AIM Congress
Apr 03, 2025, 19:14 ET 35-YEAR INDUSTRY-ACADEMIC PARTNERSHIP YIELDING GROUNDBREAKING ADVANCES FOR SCIENCE AND PATIENTS RENEWS FOR ANOTHER THREE YEARS BETWEEN LA JOLLA INSTITUTE FOR IMMUNOLOGY AND KYOWA KIRIN
life-changing value. As a Japan-based global specialty pharmaceutical company, we have invested in drug discovery and biotechnology innovation for more than 70 years. We are currently working to engineer the next generation of antibodies and cell and gene therapies with the potential
More news about: La Jolla Institute for Immunology
Apr 03, 2025, 18:35 ET ICLR Deadline: ICLR Purchasers with Losses in Excess of $100K Have Opportunity to Lead ICON plc Securities Fraud Lawsuit
were insufficient to shield ICON from the adverse effects of a significant market downturn; (3) the requests for proposals ICON received from its biotechnology customers during the Class Period were used in substantial part as price discovery tools, and thus were not indicative of underlying client demand;
More news about: THE ROSEN LAW FIRM, P. A.
Apr 03, 2025, 17:40 ET Dynavax Files Preliminary Proxy Statement
delivered total stockholder returns of approximately 300% over the past five years, far exceeding the performance of the NASDAQ Biotechnology Index and the S&P Biotechnology Select Industry Index.The Company has established HEPLISAV-B® as the market share leader in the U.S. adult Hepatitis
More news about: Dynavax Technologies
Apr 03, 2025, 16:00 ET SANA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Sana Biotechnology, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Sana Biotechnology, Inc. ("Sana" or "the Company") (NASDAQ: SANA) and certain of its officers.
More news about: Bronstein, Gewirtz & Grossman, LLC
Apr 03, 2025, 16:00 ET NETRAMARK AND WORLDWIDE CLINICAL TRIALS ANNOUNCE AGREEMENT TO TRANSFORM CLINICAL TRIAL DESIGN WITH AI-POWERED PRECISION
TrialsWorldwide Clinical Trials (Worldwide) is a full-service global contract research organization (CRO) that works in partnership with biotechnology and pharmaceutical companies to create customized solutions that advance new medications – from discovery to reality. Worldwide's capabilities include
More news about: NetraMark Holdings Inc.
Apr 03, 2025, 15:35 ET UPLIZNA® (INEBILIZUMAB-CDON) IS NOW THE FIRST AND ONLY FDA-APPROVED TREATMENT FOR IGG4-RELATED DISEASE
to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing
More news about: Amgen
Apr 03, 2025, 09:08 ET VARIANT Receives Positive Feedback from the European Medicines Agency (EMA) for its Innovative Gene Replacement Therapy, VAR002
VARIANTVariant is a biotechnology company dedicated to developing innovative gene therapy solutions for inherited retinal diseases. Variant focuses on leveraging retinal transcription
More news about: Variant
Apr 03, 2025, 05:45 ET Shareholders of Sana Biotechnology, Inc. Should Contact The Gross Law Firm Before May 20, 2025 to Discuss Your Rights - SANA
April 3, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Sana Biotechnology, Inc. (NASDAQ: SANA).
More news about: The Gross Law Firm
Apr 03, 2025, 05:45 ET The Gross Law Firm Notifies Shareholders of ICON Public Limited Company(ICLR) of a Class Action Lawsuit and an Upcoming Deadline
insufficient to shield the Company from the adverse effects of a significant market downturn; (c) the requests for proposals ICON received from its biotechnology customers during the Class Period were used in substantial part as price discovery tools, and thus were not indicative of underlying client demand;
More news about: The Gross Law Firm
Apr 02, 2025, 18:49 ET Robbins LLP Reminds SANA Investors with Large Losses to Contact the Firm for Information About the Securities Fraud Class Action Against Sana Biotechnology, Inc.
persons and entities that purchased or otherwise acquired Sana Biotechnology, Inc. (NASDAQ: SANA) securities between March 17, 2023 and November 4, 2024. Sana is a biotechnology company that develops ex vivo and in vivo cell engineering
More news about: Robbins LLP
Apr 02, 2025, 16:05 ET Curis to Present at Upcoming Healthcare Conference in April
Mass., April 2, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that James
More news about: Curis, Inc.
Apr 02, 2025, 16:00 ET ISS National Lab Launches Orbital Edge Accelerator Program to Propel Startups Into the Growing Space Economy
opportunities through the ISS National Lab to advance R&D in diverse areas, from communications and remote sensing to advanced materials and biotechnology. The impact of conducting research through the ISS National Lab is notable, as startups awarded flight projects have cumulatively raised nearly
More news about: International Space Station National Lab
Apr 02, 2025, 12:00 ET ICON plc (ICLR) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
offerings were insufficient to shield the Company from the adverse effects of a significant market downturn; (3) that the RFPs ICON received from its biotechnology customers during the Class Period were used in substantial part as price discovery tools, and thus were not indicative of underlying client demand;
More news about: Law Offices of Howard G. Smith
Apr 02, 2025, 10:44 ET The Georgia Power Foundation marks milestone, awards new grants through Workforce for Georgia program
expansion)Houston College & Career Academy – Cybersecurity Pathway AdditionNorthside High School – Enhancing Biotechnology Education for Community AdvancementTaylor County High School – The Viking Forge (Agriculture Mechanics pathway)Twiggs
More news about: Georgia Power
Apr 02, 2025, 10:01 ET Seed Coating Market to Reach $4.23 Billion by 2032, Growing at a CAGR of 7.7% from 2025--Exclusive Report by Meticulous Research®
seed treatments were primarily concerned with protecting seeds from diseases and pests. Today, modern seed coatings represent a convergence of biotechnology, chemistry, and precision agriculture, offering multifunctional capabilities that extend far beyond traditional protective mechanisms. Nanotechnology
More news about: Meticulous Market Research Pvt. Ltd.
Apr 02, 2025, 09:16 ET Lomond Therapeutics Completes Second and Third Closings and adds Two New Investors
March 28, 2025 /PRNewswire/ -- Lomond Therapeutics Holdings, Inc. ("Lomond Therapeutics"), a clinical-stage biotechnology company dedicated to discovering and developing potentially best-in-class and first-in-class medicines for the treatment of hematological malignancies,
More news about: Lomond Therapeutics
Apr 02, 2025, 09:00 ET BioMarin Announces Positive Pivotal Data for PALYNZIQ® (pegvaliase-pqpz) in Adolescents with Phenylketonuria
Prescribing Information, including Boxed Warning. About BioMarin BioMarin is a global biotechnology company dedicated to translating the promise of genetic discovery into medicines that make a profound impact on the life of each patient. The
More news about: BioMarin Pharmaceutical Inc.